1 Zegers-Hochschild F, David Adamson G, Dyer S, Racowsky C, De Mouzon J, Sokol R, et al. The International Glossary on Infertility and Fertility Care, 2017. Hum Reprod. 2017;32:1786–801.
doi:10.1093/humrep/dex234
2 Maung HH. Is infertility a disease and does it matter? Bioethics. 2019;33:43–53.
doi:10.1111/bioe.12495
3 Schwerdtfeger KL, Shreffler KM. Trauma of Pregnancy Loss and Infertility for Mothers and Involountarly Childless Women in the Contemporary United States. J Loss Trauma. 2009;14(3):211–27.
doi:10.1080/15325020802537486
4 Lechner L, Bolman C, van Dalen A. Definite involuntary childlessness: Associations between coping, social support and psychological distress. Hum Reprod. 2007;22:288–94.
doi:10.1093/humrep/del327
5 Kravdal Ø, Tverdal A, Grundy E. The association between parity, CVD mortality and CVD risk factors among Norwegian women and men. Eur J Public Health. 2020.
doi:10.1093/eurpub/ckz235
6 Inhorn MC, Patrizio P. Infertility around the globe: new thinking on gender, reproductive technologies and global movements in the 21st century. Hum Reprod Update. 2015;21:411–26.
doi:10.1093/humupd/dmv016
7 Burkimsher M, Zeman K. Childlessness in Switzerland and Austria. In: Kreyenfeld M, Konietzka D, editors. Childlessness in Europe: Contexts, Causes, and Consequences. Springer International Publishing; 2017, 115–132.
8 Kuhn M. Recht auf Kinder?: der verfassungsrechtliche Schutz des Kinderwunschs. 1st ed. Dike-Verlag; 2008.
9 L’Assemblée fédérale de la Confédération suisse. Loi fédérale sur la procréation médicalement assistée (LPMA, SR 810.11) et la Constitution fédérale de la Confédération suisse (CF, SR 101).
10 Nationale Ethikkommission. Die medizinisch unterstützte Fortpflanzung – Ethische Überlegungen und Vorschläge für die Zukunft. Stellungnahme Nr. 22/2013.
11 Seelmann K. Gutachten im Auftrag des Bundesamts für Gesundheit über «Zugang zur Fortpflanzungsmedizin für alle?». 2018.
12 Funiciello T. Frauen – ein Detail. SonntagsZeitung. 2020;27.
13 Berg Brigham K, Cadier B, Chevreul K. The diversity of regulation and public financing of IVF in Europe and its impact on utilization. Hum Reprod. 2013;28:666–75.
doi:10.1093/humrep/des418
14 Matthiesen SMS, Frederiksen Y, Ingerslev HJ, Zachariae R. Stress, distress and outcome of assisted reproductive technology (ART): A meta-analysis. Hum Reprod. 2011;26:2763–76.
doi:10.1093/humrep/der246
15 Präg P, Mills MC. Assisted Reproductive Technology in Europe: Usage and Regulation in the Context of Cross-Border Reproductive Care. In: Kreyenfeld M, Konietzka D, editors. Childlessness in Europe: Contexts, Causes, and Consequences. Springer International Publishing; 2017, 289–307.
16 Van Beers BC. Is Europe “giving in to baby markets?” Reproductive tourism in Europe and the gradual erosion of existing legal limits to reproductive markets. Med Law Rev. 2014;23:103–34.
doi:10.1093/medlaw/fwu103
17 Kälin I. Interpellation zur «Eizellspende in Schweizer IVF-Zentren». 2018.
18 Goisis A, Håberg SE, Hanevik HI, Magnus MC, Kravdal Ø. The demographics of assisted reproductive technology births in a Nordic country. Hum Reprod. 2020;35:1441–50.
doi:10.1093/humrep/deaa055
19 Dunn AL, Stafinski T, Menon D. An international survey of assisted reproductive technologies (ARTs) policies and the effects of these policies on costs, utilization, and health outcomes. Health Policy (New York). 2014;116:238–63.
doi:10.1016/J.HEALTHPOL.2014.03.006